Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

OBJECTIVE: The monoclonal antibodies anti-programmed death protein-1 (anti–PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for treatment of recurrent/metastatic head and neck carcinoma R/M HNSCC in first line and in platinum refractory disease. This netwo...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Cirillo, Alessio, Strigari, Lidia, Valentini, Filippo, Cerbelli, Bruna, Scagnoli, Simone, Cerbelli, Edoardo, Zizzari, Ilaria Grazia, Rocca, Carlo Della, D’Amati, Giulia, Polimeni, Antonella, Nuti, Marianna, Merlano, Marco Carlo, Mezi, Silvia, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380817/
https://www.ncbi.nlm.nih.gov/pubmed/34434192
http://dx.doi.org/10.3389/fimmu.2021.705096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380817/
https://www.ncbi.nlm.nih.gov/pubmed/34434192
http://dx.doi.org/10.3389/fimmu.2021.705096

Ejemplares similares